WO2002030256A3 - Diagnostic indicator of thymic function - Google Patents

Diagnostic indicator of thymic function Download PDF

Info

Publication number
WO2002030256A3
WO2002030256A3 PCT/IB2001/002351 IB0102351W WO0230256A3 WO 2002030256 A3 WO2002030256 A3 WO 2002030256A3 IB 0102351 W IB0102351 W IB 0102351W WO 0230256 A3 WO0230256 A3 WO 0230256A3
Authority
WO
WIPO (PCT)
Prior art keywords
patient
monitored
level
diagnostic indicator
thymus
Prior art date
Application number
PCT/IB2001/002351
Other languages
French (fr)
Other versions
WO2002030256A2 (en
WO2002030256A9 (en
Inventor
Richard Boyd
Original Assignee
Richard Boyd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR0745A external-priority patent/AUPR074500A0/en
Priority claimed from US09/755,965 external-priority patent/US20010046486A1/en
Priority to IL15541201A priority Critical patent/IL155412A0/en
Priority to BR0114644-0A priority patent/BR0114644A/en
Priority to KR10-2003-7005251A priority patent/KR20030076572A/en
Priority to JP2002533706A priority patent/JP2004523730A/en
Application filed by Richard Boyd filed Critical Richard Boyd
Priority to NZ525826A priority patent/NZ525826A/en
Priority to EP01986579A priority patent/EP1365790A4/en
Priority to CA002462758A priority patent/CA2462758A1/en
Priority to AU2002218450A priority patent/AU2002218450A1/en
Publication of WO2002030256A2 publication Critical patent/WO2002030256A2/en
Publication of WO2002030256A3 publication Critical patent/WO2002030256A3/en
Publication of WO2002030256A9 publication Critical patent/WO2002030256A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5418—IL-7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/5759—Thymosin or related peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2550/00—Electrophoretic profiling, e.g. for proteome analysis

Abstract

The present disclosure provides a method for determining whether a patient's immune system can be modified through stimulation of thymus function. In a preferred embodiment, sex steroids are ablated in the patient, and the resulting production of thymic factors is monitored. In particular, the level of these factors in the patient's blood stream is observed. In another embodiment, the level of new T cells is monitored. An early response, such as within hours or days of the ablation, indicates that the patient's thymus is disposed to regeneration through sex steroid ablation.
PCT/IB2001/002351 2000-10-13 2001-10-12 Diagnostic indicator of thymic function WO2002030256A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2002218450A AU2002218450A1 (en) 2000-10-13 2001-10-12 Diagnostic indicator of thymic function
CA002462758A CA2462758A1 (en) 2000-10-13 2001-10-12 Diagnostic indicator of thymic function
BR0114644-0A BR0114644A (en) 2000-10-13 2001-10-12 Thermal function diagnostic indicator
KR10-2003-7005251A KR20030076572A (en) 2000-10-13 2001-10-12 Diagnostic Indicator of Thymic Function
JP2002533706A JP2004523730A (en) 2000-10-13 2001-10-12 Thymic function diagnostic indicator
IL15541201A IL155412A0 (en) 2000-10-13 2001-10-12 Diagnostic indicator of thymic function
NZ525826A NZ525826A (en) 2000-10-13 2001-10-12 Diagnostic indicator of thymic function
EP01986579A EP1365790A4 (en) 2000-10-13 2001-10-12 Diagnostic indicator of thymic function

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US79528600A 2000-10-13 2000-10-13
US79530200A 2000-10-13 2000-10-13
US09/795,302 2000-10-13
AUPR0745A AUPR074500A0 (en) 2000-10-13 2000-10-13 Treatment of t cell disorders
AUPR0745 2000-10-13
US09/795,286 2000-10-13
US75598301A 2001-01-05 2001-01-05
US75564601A 2001-01-05 2001-01-05
US09/755,646 2001-01-05
US09/755,965 2001-01-05
US09/755,983 2001-01-05
US09/755,965 US20010046486A1 (en) 2000-04-17 2001-01-05 Stimulation of thymus for vaccination development
US75891001A 2001-01-10 2001-01-10
US09/758,910 2001-01-10
US09/885,268 US20030017153A1 (en) 2000-10-13 2001-08-01 Diagnostic indicator of thymic function
US09/885,268 2001-08-01

Publications (3)

Publication Number Publication Date
WO2002030256A2 WO2002030256A2 (en) 2002-04-18
WO2002030256A3 true WO2002030256A3 (en) 2002-07-25
WO2002030256A9 WO2002030256A9 (en) 2003-09-12

Family

ID=27570137

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/002351 WO2002030256A2 (en) 2000-10-13 2001-10-12 Diagnostic indicator of thymic function

Country Status (8)

Country Link
EP (1) EP1365790A4 (en)
JP (1) JP2004523730A (en)
CN (1) CN1516597A (en)
AU (1) AU2002218450A1 (en)
CA (1) CA2462758A1 (en)
IL (1) IL155412A0 (en)
NZ (1) NZ525826A (en)
WO (1) WO2002030256A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103173534B (en) * 2012-11-20 2014-08-06 无锡联合利康临床检验所有限公司 Real-time fluorescence quantitative PCR (polymerase chain reaction) kit for quantitatively detecting TRECs gene and application thereof

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102772783A (en) * 2007-01-25 2012-11-14 中国生化制药工业协会 Application of serum thymus factor in preparation of protecting drugs of antineoplastic drugs, and tumour physical and chemical treatment drugs
ES2331499B1 (en) * 2007-08-02 2010-10-14 Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud En Sevilla (Fund.Sevilla) PRIMERS, PROCEDURE AND SET OF USEFULS FOR THE DETERMINATION OF THE FUNCTIONALITY OF THE HUMAN TIMO.
BRPI0819854B1 (en) * 2007-11-27 2019-06-04 Veridex, Llc A method for isolating, enriching and analyzing circulating melanoma cells in a blood sample
DE102008057479A1 (en) 2008-11-14 2010-05-20 Bernhard, Stefan, Dr. Immune defense stimulating method for immune system of human body during treatment of e.g. aids, involves exciting thymus gland by stimulations e.g. thermal stimulations, and transferring energy from resonance body to thymus gland
EP2525727A4 (en) 2010-01-19 2017-05-03 The Board of Regents of The University of Texas System Apparatuses and systems for generating high-frequency shockwaves, and methods of use
AR087170A1 (en) 2011-07-15 2014-02-26 Univ Texas APPARATUS FOR GENERATING THERAPEUTIC SHOCK WAVES AND ITS APPLICATIONS
US10835767B2 (en) 2013-03-08 2020-11-17 Board Of Regents, The University Of Texas System Rapid pulse electrohydraulic (EH) shockwave generator apparatus and methods for medical and cosmetic treatments
US11229575B2 (en) 2015-05-12 2022-01-25 Soliton, Inc. Methods of treating cellulite and subcutaneous adipose tissue
TWI742110B (en) 2016-07-21 2021-10-11 美商席利通公司 Rapid pulse electrohydraulic (eh) shockwave generator apparatus with improved electrode lifetime and method of producing compressed acoustic wave using same
BR112019017264A2 (en) 2017-02-19 2020-04-14 Soliton Inc selective laser-induced optical rupture in biological medium

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000062657A2 (en) * 1999-04-15 2000-10-26 Monash University Improvement of t cell mediated immunity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000062657A2 (en) * 1999-04-15 2000-10-26 Monash University Improvement of t cell mediated immunity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
WINDMILL K.F. AND LEE V.W.K.: "Effects of castration on the lymphocytes of the thymus, spleen and lymph nodes", TISSUE & CELL, vol. 30, no. 1, 1998, pages 104 - 111, XP004977834 *
WINDMILL K.F. AND LEE V.W.K.: "Influences of surgical castration on the thymus of male rats", JOURNAL OF REPRODUCTIVE IMMUNOLOGY, vol. 44, 1999, pages 29 - 39, XP002971218 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103173534B (en) * 2012-11-20 2014-08-06 无锡联合利康临床检验所有限公司 Real-time fluorescence quantitative PCR (polymerase chain reaction) kit for quantitatively detecting TRECs gene and application thereof

Also Published As

Publication number Publication date
CN1516597A (en) 2004-07-28
EP1365790A4 (en) 2006-05-31
CA2462758A1 (en) 2002-04-18
IL155412A0 (en) 2003-11-23
EP1365790A2 (en) 2003-12-03
AU2002218450A1 (en) 2002-04-22
JP2004523730A (en) 2004-08-05
NZ525826A (en) 2006-06-30
WO2002030256A2 (en) 2002-04-18
WO2002030256A9 (en) 2003-09-12

Similar Documents

Publication Publication Date Title
Myers et al. White coat effect in treated hypertensive patients: sex differences
WO2002030256A3 (en) Diagnostic indicator of thymic function
WO2003011354A3 (en) Membrane for use with implantable devices
EP0796592A3 (en) Disposable lancet
AU2002327308A1 (en) Methods for evaluating pathologic conditions using extracellular rna
EP0826391A3 (en) Apparatus and method for detecting progression of AV nodal block and atrial capture using atrial lead
WO2003069332A3 (en) Detection and/or monitoring of synuclein-related diseases
WO2000018954A3 (en) Use of pex in the treatment of metabolic bone diseases
EP0896828A3 (en) An active implantable patient monitoring device
WO2001002050A3 (en) Method and system for use in treating a patient with any drug to optimize therapy and prevent an adverse drug response
HUS1900041I1 (en) Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation
EP0404210A3 (en) A method and probe for the detection of cells associated with human oral medical disorders or with healthy human gingiva
EP1162457A3 (en) Multiple coagulation test system and method of using a multiple coagulation test system
EP0525917A3 (en) Double-stranded rna correction of aberrant metabolic pathways associated with uncontrolled tumor cell and virus growth cycles
HUP9901188A2 (en) New defined enzyme mixtures for obtaining cells and treating wounds
WO1999051720A3 (en) Methods for production of therapeutic cytokines
WO2000066732A3 (en) Laminin 8 and methods for its use
WO1998042737A3 (en) Peptides for the treatment of systemic lupus erythematosus
WO2001029070A8 (en) Modulation of t cell differentiation for the treatment of t helper cell mediated diseases
Tschopp et al. Defective platelet adhesion and aggregation on subendothelium exposed in vivo or in vitro to flowing blood of fawn-hooded rats with storage pool disease
Hiroyuki et al. Studies on kallikrein-kinin system in plasma of patients with acute pancreatitis
WO2004018504A3 (en) Immune markers used for diagnosis and therapy in connection with transplant reactions
AU4484593A (en) Method for the determination of lupus anticoagulant antibodies that cause thrombosis
WO2000073338A8 (en) Compositions and methods for the therapy, diagnosis and monitoring of breast cancer
EP0786077A4 (en) Method for the diagnosis of depression based on monitoring blood levels of arginine vasopressin and/or thymopoietin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002533706

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 155412

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1020037005251

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2001986579

Country of ref document: EP

Ref document number: 525826

Country of ref document: NZ

Ref document number: 2002218450

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 018201512

Country of ref document: CN

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

COP Corrected version of pamphlet

Free format text: PAGES 1/34-34/34, DRAWINGS, REPLACED BY NEW PAGES 1/27-27/27; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWP Wipo information: published in national office

Ref document number: 1020037005251

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001986579

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2462758

Country of ref document: CA